Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection
- PMID: 9746073
- DOI: 10.1002/(sici)1096-9071(199810)56:2<159::aid-jmv10>3.0.co;2-b
Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection
Abstract
To monitor early and late events of immune system activation after primary and secondary flavivirus infection, 17 healthy persons were vaccinated with the standard 17D vaccine virus strain of yellow fever (YF). Twelve of these persons had not received YF vaccine previously and 5 had been vaccinated once at least 10 years before. Viremia and various parameters of humoral and cellular immune activation were followed daily for 7 days and weekly thereafter. Viremia was detected by reverse transcriptase-polymerase chain reaction in all 12 first-time vaccinees beginning from the second to the sixth day after vaccination; most tested positive between the fourth and sixth day. Infectious 17D virus was detected using a plaque forming assay in the serum of 7 of the 12 first-time vaccinees. As first parameters of immune activation, neopterin and beta2-microglobulin markedly increased between day 2 and day 6 postvaccination. In parallel to the viremia, circulating CD8+ T-cells significantly increased, with peak levels at day 5 after primary vaccination, indicating an activation of the cellular immune system. Neither viremia nor significant changes of these activation markers were observed in the five revaccinated persons. Neutralizing antibodies directed against the 17D vaccine strain developed in all persons within 2 weeks after vaccination. No correlation was found between the extent of viremia and the titer of neutralizing antibodies. Revaccination was followed by a minor and transient increase of neutralizing antibodies. High titers of neutralizing antibodies persisted for at least 10 years after primary vaccination.
Similar articles
-
Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus.Mem Inst Oswaldo Cruz. 2005 May;100(3):331-7. doi: 10.1590/s0074-02762005000300021. Epub 2005 Aug 15. Mem Inst Oswaldo Cruz. 2005. PMID: 16113878
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584
-
Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.J Clin Invest. 2014 Jul;124(7):3147-58. doi: 10.1172/JCI75429. Epub 2014 Jun 9. J Clin Invest. 2014. PMID: 24911151 Free PMC article. Clinical Trial.
-
Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.Vaccine. 2017 Oct 20;35(44):5951-5955. doi: 10.1016/j.vaccine.2017.03.032. Epub 2017 Mar 30. Vaccine. 2017. PMID: 28366605 Review.
-
Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D.Adv Exp Med Biol. 2007;590:43-53. doi: 10.1007/978-0-387-34814-8_3. Adv Exp Med Biol. 2007. PMID: 17191376 Review. No abstract available.
Cited by
-
Inadvertent yellow fever vaccination of a patient with Crohn's disease treated with infliximab and methotrexate.BMJ Case Rep. 2016 Aug 29;2016:bcr2016215403. doi: 10.1136/bcr-2016-215403. BMJ Case Rep. 2016. PMID: 27571912 Free PMC article.
-
17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.Hum Vaccin Immunother. 2013 Apr;9(4):879-88. doi: 10.4161/hv.22982. Epub 2013 Jan 30. Hum Vaccin Immunother. 2013. PMID: 23364472 Free PMC article. Clinical Trial.
-
Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium.Sci Rep. 2019 Dec 30;9(1):20362. doi: 10.1038/s41598-019-56994-8. Sci Rep. 2019. PMID: 31889148 Free PMC article.
-
Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines.J Exp Med. 2019 Sep 2;216(9):2057-2070. doi: 10.1084/jem.20182295. Epub 2019 Jul 3. J Exp Med. 2019. PMID: 31270247 Free PMC article.
-
Markers of innate immune function are associated with vitamin a stores in men.J Nutr. 2009 Feb;139(2):377-85. doi: 10.3945/jn.108.100198. Epub 2008 Dec 17. J Nutr. 2009. PMID: 19091796 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials